11-ITEM EoE IMPACT QUESTIONNAIRE

The 11-Item EoE Impact Questionnaire (EoE-IQ)is a patient-reported assessment that measures the emotional, social, productivity, and sleep-related impacts of eosinophilic esophagitis.3

HOW THE EoE-IQ IS SCORED

Patients record responses to questions that evaluate quality of life using a 5-point response option ranging from “Not at all” to “Extremely.” The maximum score is 5.3

EoE-IQ QUESTIONNAIRE3 0
(Not at all)
1 2 3 4 5
(Extremely)

DURING THE PAST 7 DAYS, WERE YOU...

1. Bothered by symptoms of EoE

2. Worried about trouble swallowing

3. Worried about choking

4. Embarrassed

5. Worried about trouble swallowing while in a public place

6. Difficulty taking part in social activities that involve eating food

7. Impact of EoE on relationships with family

8. Impact of EoE on relationships with friends

9. Difficulty keeping up with things at work or school

10. Missing work or school

11. Sleep disruption

Total Score = 0

Print this form
HIGHER SCORES INDICATE GREATER IMPACT ON HEALTH-RELATED QUALITY OF LIFE3
1 (no impact) 5 (highest impact)
    1. O’Shea KM, Aceves SS, Dellon ES, et al. Pathophysiology of eosinophilic esophagitis. Gastroenterology. 2018;154(2):333-345. doi:10.1053/j.gastro.2017.06.065
    2. Hudgens S, Evans C, Phillips E, Hill M. Psychometric validation of the Dysphagia Symptom Questionnaire in patients with eosinophilic esophagitis treated with budesonide oral suspension. J Patient Rep Outcomes. 2017;1(3):1-11. doi:10.1186/s41687-017-0006-5
    3. Dellon ES, et al. Dupilumab improves health-related quality of life and reduces symptom burden in patients with eosinophilic esophagitis: results from part A of a randomized, placebo-controlled, three-part, phase 3 study. Poster presented at: 2021 Virtual Annual Meeting of the American Academy of Allergy, Asthma, and Immunology (AAAAI); February 26 - March 1, 2021.
    4. Dellon ES, Gupta SK. A conceptual approach to understanding treatment response in eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2019;17(11):2149-2160. doi:10.1016/j.cgh.2019.01.030
    5. Wen T, Stucke EM, Grotjan TM, et al. Molecular diagnosis of eosinophilic esophagitis by gene expression profiling. Gastroenterology. 2013;145(6):1289-1299. doi:10.1053/j.gastro.2013.08.046
    6. Dellon ES, Veerappan R, Selitsky SR, et al. A gene expression panel is accurate for diagnosis and monitoring treatment of eosinophilic esophagitis in adults. Clin Transl Gastroenterol. 2017;8(2):1-8. doi:10.1038/ctg.2017.2
    7. Collins MH, et al. Newly developed and validated eosinophilic esophagitis histology scoring system and evidence that it outperforms peak eosinophil count for disease diagnosis and monitoring. Dis Esophagus. 2017;30(3):1-8. doi:10.1111/dote.12470
    8. Wechsler JB, et al. Eosinophilic esophagitis reference score accurately identifies disease activity and treatment effects in children. Clin Gastroenterol Hepatol. 2018;16(7):1056-1063. doi:10.1016/j. cgh.2017.12.019
    9. Hirano I, et al. Endoscopic assessment of the oesophageal features of eosinophilic oesophagitis: validation of a novel classification and grading system. Gut. 2013;62(4):489-495. doi:10.1136/ gutjnl-2011-301817
    10. Lucendo AJ, Molina-Infante J, Arias Á, et al. Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults. United European Gastroenterol J. 2017;5(3):335-358. doi:10.1177/2050640616689525
    11. Safroneeva E, Straumann A, Coslovsky M, et al; International Eosinophilic Esophagitis Activity Index Study Group. Symptoms have modest accuracy in detecting endoscopic and histologic remission in adults with eosinophilic esophagitis. Gastroenterology. 2016;150(3):581-590.e4. doi:10.1053/j.gastro.2015.11.004
    12. COREOS Collaborators: Ma C, Schoepfer AM, et al. Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS) [published online ahead of print, 2021 Jul 6]. J Allergy Clin Immunol. 2021;S0091-6749(21)01059-9. doi:10.1016/j.jaci.2021.07.001

MAT-BH-2200615/V1/August 2022